Chung, Hye J. Lee, Myung G. 2024-01-21T02:30:28Z 2024-01-21T02:30:28Z 2021-08-31 2006-10 0142-2782 https://pubs.kist.re.kr/handle/201004/135095 Pharmacokinetic parameters of ipriflavone were compared after intravenous (20 mg/kg) and oral (200 mg/kg) administration in control rats and in rats with acute renal failure induced by uranyl nitrate (U-ARF rats). It was expected that the time-averaged nonrenal clearance (Cl-nr) of ipriflavone in U-ARF rats could be significantly slower than in the control rats, since it was reported that ipriflavone was metabolized via the hepatic microsomal cytochrome P450 (CYP) 1A1/2 and 2C11 and the expression and mRNA level of CYP1A2 were not changed, but those of CYP2C11 were decreased in U-ARF rats compared with control rats. Unexpectedly, after intravenous administration in U-ARF rats, the Cl-nr, of ipriflavone was significantly faster than in the controls (40.8 compared with 29.0ml/min/kg). This may be due to an increase in the glucuronide conjugate formation of ipriflavone metabolites in U-ARF rats. After oral administration of ipriflavone in U-ARF rats, the AUC(0-24h) was significantly smaller (194 compared with 295 mu g min/ml) than in the controls. Copyright (c) 2006 John Wiley & Sons, Ltd. English JOHN WILEY & SONS LTD POSTMENOPAUSAL OSTEOPOROSIS CYP2E1 INDUCTION DOSAGE REGIMENS PLASMA BONE METABOLITES LIVER Pharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate Article 10.1002/bdd.515 1 BIOPHARMACEUTICS & DRUG DISPOSITION, v.27, no.7, pp.345 - 351 BIOPHARMACEUTICS & DRUG DISPOSITION 27 7 345 351 scie scopus 000241997900005 Pharmacology & Pharmacy Pharmacology & Pharmacy Article POSTMENOPAUSAL OSTEOPOROSIS CYP2E1 INDUCTION DOSAGE REGIMENS PLASMA BONE METABOLITES LIVER ipriflavone U-ARF pharmacokinetics rats